Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer
Shots:
- The FDA’s BT designation is based on P-III MONALEESA-7 study assessing Kisqali + tamoxifen/ aromatase inhibitor + goserelin vs tamoxifen/aromatase inhibitor + goserelin in 672 pre/perimenopausal women with HR+/HER2- advanced breast cancer
- The P-III MONALEESA-7 study results: mPFS (22.1- 27.5 vs 11.0- 13.8 mos.); AEs: neutropenia (60.6% vs. 3.6%); leukopenia (14.3% vs. 1.2%); no new safety signals observed
- Kisqali (ribociclib) is a CDK4/6 (cyclin-dependent kinase) inhibitor- approved in the US for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer in combination with aromatase inhibitor and has received its first BT designation based on P-III MONALEESA-2 study in Aug’16.
Ref: Novartis | Image: Value Walk
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com